MOLN
Molecular Partners AG

187
Loading...
Loading...
News
all
press releases
Molecular Partners Publishes Invitation to Annual General Meeting 2024
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...
Globe Newswire·1y ago
News Placeholder
More News
News Placeholder
Full Year 2023 Molecular Partners AG Earnings Call Transcript
Related Stocks: OTCPK:MLLCF...
GuruFocus·1y ago
News Placeholder
Molecular Partners AG (MOLN) Q4 2023 Earnings Call Transcript
Molecular Partners AG (MOLN) Q4 2023 Earnings Call Transcript...
SeekingAlpha·1y ago
News Placeholder
Molecular Partners Reports Corporate Highlights From Q4 2023 and Key Financials for Full Year 2023
Research & Development Highlights Presented encouraging initial data from first four dosing cohorts of ongoing Phase 1/2a trial of MP0533 for patients with relapsed/refractory AML and AML/MDS at the...
Globe Newswire·1y ago
News Placeholder
Molecular Partners Announces Dismissal of Class Action Lawsuit
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 01, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...
Globe Newswire·2y ago
News Placeholder
Molecular Partners To Hold Conference Call to Discuss Fourth Quarter and Full Year 2023 Results and Announces Upcoming Investor Presentations
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 01, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...
Globe Newswire·2y ago
News Placeholder
Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference
Tetra-specific T-cell engager MP0533 for patients with r/r AML and AML/MDS on track to deliver expanded clinical phase 1/2a data in H1 2024Progress of Radio-DARPin Therapy (RDT) platform: Improved...
Globe Newswire·2y ago
News Placeholder
Molecular Partners and Orano Med Announce Co-Development Agreement for Radio-DARPin Therapies
Collaboration leverages lead-based (212Pb) alpha emitter expertise and supply of Orano Med with Molecular Partners' leadership in DARPins for tumor-targeted delivery of radioactive...
Globe Newswire·2y ago

Latest MOLN News

View

Advertisement. Remove ads.

Advertisement. Remove ads.

Advertisement. Remove ads.